Editorial review
Educational content is reviewed for source quality, clinical boundaries, and readability. It is not medical advice; confirm care decisions with a licensed clinician.
How CYP3A4 Shapes What an Oral Ketamine Tablet Actually Does
CYP3A4 (cytochrome P450 3A4) is a liver and gut-wall enzyme that breaks down most of a swallowed ketamine tablet before the drug ever reaches your bloodstream in its original form. This process, called first-pass metabolism, is the main reason oral ketamine has much lower bioavailability than intravenous (IV) ketamine, and it's a key reason prescribers ask detailed questions about your other medications, supplements, and even certain foods. Along with a second enzyme, CYP2B6, CYP3A4 converts ketamine into norketamine and other metabolites, some of which have their own effects on the body. Understanding this enzyme pathway helps explain why oral ketamine dosing is individualized, why some drug combinations get flagged during intake, and why the same tablet dose can feel different depending on what else is in your system that day.
Quick Answer
CYP3A4 is a liver and intestinal enzyme that metabolizes most of an oral ketamine tablet before it reaches systemic circulation, a process called first-pass metabolism. This is a major reason oral ketamine's bioavailability is far lower than IV ketamine's, and it converts a large share of the dose into norketamine, an active metabolite. Medications or substances that inhibit or induce CYP3A4, such as certain antifungals, antibiotics, anticonvulsants, or grapefruit juice, can raise or lower ketamine blood levels, which is why prescribers screen for these interactions before and during treatment. This is educational information, not medical advice; talk to your prescriber about how it applies to your specific medications.
Where CYP3A4 Does Its Work
CYP3A4 is concentrated in the liver and, in smaller amounts, in the lining of the small intestine. When you swallow a ketamine tablet, the drug passes through the gut wall and then the liver before it enters general circulation, and both tissues contain CYP3A4 ready to metabolize it. This double exposure is part of why swallowed tablets lose more drug to metabolism than routes that partially or fully bypass the liver's first pass, such as sublingual (under-the-tongue) dosing or IV administration. See our guide on ketamine bioavailability explained why sublingual administration matters for how absorption route changes the amount of active drug that ultimately reaches your bloodstream, and peak plasma levels for how quickly that drug shows up once absorbed.
Compare tablet options
Review tablets versus troches, IV infusion, and other routes before deciding what to ask.
Compare optionsBioavailability by Route
Norketamine: The Metabolite CYP3A4 Creates
When CYP3A4 and CYP2B6 break down ketamine, one of the main byproducts is norketamine, a metabolite that is itself pharmacologically active, though generally considered less potent than the parent drug. Because oral and sublingual dosing route more of the tablet through first-pass metabolism than IV administration does, oral and sublingual patients typically end up with a higher ratio of norketamine to ketamine in their bloodstream compared with patients receiving IV infusions. Some researchers and clinicians consider this a relevant factor in how oral ketamine's effects and duration differ from infusion-based protocols, though the clinical significance of the norketamine ratio specifically is still an area of active study. For more on this metabolite's role, read norketamine's role as an active metabolite, and for how long metabolites persist after a dose, see how long does a ketamine tablet stay in your system.
Drug and Supplement Interactions to Flag
Because CYP3A4 processes a large share of an oral ketamine dose, anything that inhibits or induces this enzyme can meaningfully change how much active drug reaches your bloodstream. Known CYP3A4 inhibitors, including certain antifungal medications, some antibiotics such as clarithromycin, and grapefruit juice, can raise ketamine levels and increase side-effect risk. Known CYP3A4 inducers, such as St. John's Wort and some anticonvulsants like carbamazepine, can lower ketamine levels enough to blunt the intended effect. Give your prescriber a complete, current list of medications and supplements before starting oral ketamine tablets, and update them whenever that list changes.
Why This Belongs in Your Prescriber's Screening Questions
This enzyme pathway is a core reason a legitimate oral ketamine intake includes a detailed medication and supplement history, not just a diagnosis check. The FDA maintains a reference table of known CYP3A4 substrates, inhibitors, and inducers that clinicians use to anticipate interaction risk across many drugs, not ketamine alone. Researchers studying ketamine's pharmacokinetics have documented CYP3A4 and CYP2B6 as the primary enzymes involved in its metabolism; you can review the underlying literature through a PubMed search on ketamine CYP3A4/CYP2B6 metabolism. Separate from enzyme interactions, what you eat or drink around dosing time can also change how much drug gets absorbed in the first place, see food antacids oral ketamine absorption for timing guidance, and monitoring your response to ketamine tablet for what your care team typically tracks across a treatment course. Because oral ketamine is prescribed off-label and compounded rather than FDA-approved for depression, evidence on its pharmacokinetics and interaction profile is still more limited than for IV ketamine or Spravato (esketamine), the only ketamine-derived treatment with FDA approval for treatment-resistant depression. See oral ketamine safety and efficacy: the evidence for an honest look at what the research does and doesn't yet show.
Action Checklist Before Starting Tablets
- List every prescription medication, over-the-counter drug, and supplement for your prescriber before starting oral ketamine tablets
- Ask specifically whether grapefruit or grapefruit juice is a concern with your prescribed dose
- Flag any recent start or stop of antibiotics, antifungals, anticonvulsants, or herbal supplements like St. John's Wort
- Report any unexpected change in how a dose feels rather than adjusting the dose yourself, since it may reflect an enzyme interaction
- Update your medication list with your prescriber at every follow-up, not just at intake
Keep Learning About Oral Ketamine
Understand how a legitimate oral ketamine prescription is evaluated, dosed, and monitored so you can have an informed conversation with your provider.
Frequently Asked Questions
Grapefruit and grapefruit juice contain compounds that inhibit intestinal CYP3A4, which can raise blood levels of drugs that rely on this enzyme for first-pass metabolism, including oral ketamine. Ask your prescriber directly whether grapefruit products are a concern with your specific dose and formulation.
Sublingual (under-the-tongue) dosing allows some of the drug to absorb directly into blood vessels under the tongue, partially bypassing the gut-wall and liver CYP3A4 metabolism that a swallowed tablet undergoes. This is one reason sublingual bioavailability tends to run higher than swallowed-tablet bioavailability. See ketamine bioavailability explained why sublingual administration matters for more detail.
Individual variability in CYP3A4 and CYP2B6 activity, whether from genetics, age, liver function, or other medications, can plausibly affect how much active ketamine and norketamine a given dose produces. Research specifically quantifying this variability for oral ketamine dosing is still limited, which is part of why prescribers start conservatively and adjust based on your response.
CYP3A4, along with CYP2B6, is one of the enzymes that converts ketamine into norketamine, an active metabolite. Because oral and sublingual routes send more of the dose through first-pass liver metabolism than IV administration, they tend to produce a higher relative amount of norketamine. Read more in norketamine's role as an active metabolite.
Share
Related Reading
Contact Ketamine Tablet
Send corrections, provider questions, or advertising inquiries.